Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
J Med Virol ; 93(3): 1739-1742, 2021 03.
Article in English | MEDLINE | ID: covidwho-1206811


Here we present results from a survey on anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in healthy blood donors from a low incidence coronavirus disease 2019 area (Apulia region, South Eastern Italy). Among 904 subjects tested, only in nine cases (0.99%) antibodies against SARS-CoV-2 were demonstrated. All the nine seropositive patients were negative for the research of viral RNA by reverse transcription polymerase chain reaction in nasopharyngeal swabs. These data, along with those recently reported from other countries, clearly show that we are very far from herd immunity and that the containment measures are at the moment the only realistic instrument we have to slow the spread of the pandemic.

COVID-19/immunology , Immunity, Herd/immunology , SARS-CoV-2/immunology , Adolescent , Adult , Aged , Antibodies, Viral/immunology , Blood Donors , Female , Humans , Italy , Male , Middle Aged , Pandemics/prevention & control , RNA, Viral/immunology , Young Adult
Int J Environ Res Public Health ; 17(24)2020 12 13.
Article in English | MEDLINE | ID: covidwho-970982


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the first coronavirus that has caused a pandemic. Assessing the prevalence of anti-SARS-CoV-2 in healthcare worker groups offers a unique opportunity to study the correlation between seroconversion and immunization because of their occupational exposure and a higher risk of contagion. The study enrolled 3242 asymptomatic employees of "Policlinico Riuniti", Foggia. After the first screening, we collected sequential serum samples for up to 23 weeks from the same subjects. In order to perform a longitudinal follow-up study and get information about the titration of IgG levels, we analyzed data from subjects (33) with at least two consecutive serological IgG-positive tests; 62 (1.9%; 95% CI: 1.4-2.3) tested positive for at least one anti-SARS-CoV-2 antibody. The seroprevalence was lower in the high-risk group 1.4% (6/428; 95% CI: 0.5-2.6) vs. the intermediate-risk group 2.0% (55/2736; 95% CI: 1.5-2.5). Overall, within eight weeks, we detected a mean reduction of -17% in IgG levels. Our data suggest a reduction of about 9.27 AU/mL every week (R2 = 0.35, p = 0.0003). This study revealed the prevalence of SARS-CoV-2 antibodies among Foggia's hospital healthcare staff (1.9%). Moreover, the IgG level reduction suggests that the serological response fades fast in asymptomatic infections.

Antibodies, Viral/blood , COVID-19/immunology , Health Personnel , Seroepidemiologic Studies , Adult , COVID-19/blood , Delivery of Health Care , Follow-Up Studies , Hospitals , Humans , Immunoglobulin G/blood , Italy/epidemiology , Middle Aged